Ranbaxy slumps to Q3 loss on forex woes
This article was originally published in Scrip
Ranbaxy Laboratories reported a net loss of INR4.5bn ($73.8m) in the third quarter ended September, impacted by foreign exchange charges and a provision for stock write-off at its tainted Mohali site, among other exceptional factors, compared with a net profit of INR7.54bn for the same quarter of the previous year.
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.